Drug Interactions in Insulin Therapy Among Patients with Type 1 Diabetes Mellitus: A Retrospective Study
Article Sidebar
Main Article Content
Page: 2738-2748
Abstract
Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune disorder resulting in the destruction of pancreatic β-cells, leading to absolute insulin deficiency and hyperglycemia. Insulin remains the cornerstone of therapy; however, its use may be complicated by drug interactions that alter treatment effectiveness through pharmacodynamic or pharmacokinetic mechanisms. This study aimed to evaluate the prevalence and mechanisms of potential insulin drug interactions in patients with T1DM. A retrospective, cross-sectional study was conducted using a total sampling method. The study was conducted at Dr. M. Djamil General Hospital Padang. The study population consisted of all hospitalized patients diagnosed with type 1 diabetes mellitus (T1DM) during the period 2019–2022. Patient characteristics, patterns of insulin therapy, and the occurrence of drug interactions were analyzed. The majority of patients were female (70%), and most were in the 0–18-year age group (83%). Insulin therapy was prescribed in 86.6% of cases. Potential drug–drug interactions were identified in 33.3% of hospitalized patients with type 1 diabetes mellitus, predominantly pharmacodynamic in nature. The basal–bolus insulin regimen constituted the most frequently prescribed therapeutic option among the patients. The Spearman correlation analysis indicated a statistically insignificant association between the metric of polypharmacy and the incidence of drug interactions. Systematic monitoring remains essential, and larger prospective studies are needed to confirm these findings.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383(9911):69-82. DOI: https://doi.org/10.1016/S0140-6736(13)60591-7
Redondo MJ, Eisenbarth GS. Genetic control of autoimmunity in Type I diabetes and associated disorders. Diabetologia. 2002;45(5):605-22. DOI: https://doi.org/10.1007/s00125-002-0781-1
Gianani R, Eisenbarth GS. The stages of type 1A diabetes: 2005. Immunol Rev. 2005;204:232-49. DOI: https://doi.org/10.1111/j.0105-2896.2005.00248.x
Thompson MJ, Boulton J, Jepson J, et al. Pathophysiology of β-cell destruction in type 1 diabetes. Bull Natl Res Cent. 2023;47:102. doi:10.1186/s42269-024-01197-z. DOI: https://doi.org/10.1186/s42269-024-01197-z
Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med. 2000;342(5):301-7. DOI: https://doi.org/10.1056/NEJM200002033420501
Misra, S., & Shukla, A. K. (2023). Teplizumab: type 1 diabetes mellitus preventable?. European journal of clinical pharmacology, 79(5), 609–616. https://doi.org/10.1007/s00228-023-03474-8 DOI: https://doi.org/10.1007/s00228-023-03474-8
International Diabetes Federation. IDF Diabetes Atlas, 10th ed. Brussels, Belgium: International Diabetes Federation; 2021.
National Institute of Health Research and Development (NIHRD). National Basic Health Research (Riskesdas) 2018. Ministry of Health, Republic of Indonesia; 2019.
PERKENI (Perkumpulan Endokrinologi Indonesia). Consensus on the Management and Prevention of Type 2 Diabetes Mellitus in Indonesia. Jakarta: PERKENI; 2015.
Kementerian Kesehatan RI. Survey Kesehatan Indonesia (Indonesia Health Survey) 2023: Laporan Nasional. Jakarta: Badan Kebijakan Pembangunan Kesehatan; 2023
National Institutes of Health. What is a Drug Interaction? [Internet]. United States: NIH; 2025 [cited 2025 Sep 11]. Available from: https://clinicalinfo.hiv.gov/en/what-drug-interaction
Food–Drug Interactions. Oman Med J [Internet]. 2011 [cited 2025 Sep 11];26(2):77-83. Available from: https://doaj.org/article/4be79a1229744787a002095f40597321 DOI: https://doi.org/10.5001/omj.2011.21
Baxter K, Preston CL, editors. Stockley’s Drug Interactions. 12th ed. London: Pharmaceutical Press; 2022.
Tatro DS. Drug Interaction Facts. St. Louis: Wolters Kluwer Health; 2020.
Erlisa. Analisis Potensi Interaksi Antidiabetik Injeksi Insulin pada Peresepan Rawat Jalan di RSUD Dokter Soedarso Pontianak. J Sains Kesehat. 2021;3(2):150–8.
Djahido MR. Profil Penggunaan Insulin pada Pasien Diabetes Melitus Tipe 1 di RSUD Prof. Dr. W. Z. Johannes Kupang. Jurnal Info Kesehatan. 2020;18(1):64-70. DOI: https://doi.org/10.35799/pha.9.2020.27413
Patterson, C. C., Harjutsalo, V., Rosenbauer, J., Neu, A., Cinek, O., Skrivarhaug, T., Rami-Merhar, B., Soltesz, G., Svensson, J., Parslow, R. C., Castell, C., Schoenle, E. J., Bingley, P. J., Dahlquist, G., Jarosz-Chobot, P. K., Marčiulionytė, D., Roche, E. F., Rothe, U., Bratina, N., Ionescu-Tirgoviste, C., … Green, A. (2019). Trends and cyclical variation in the incidence of childhood type 1 diabetes in 26 European centres in the 25 year period 1989-2013: a multicentre prospective registration study. Diabetologia, 62(3), 408–417. https://doi.org/10.1007/s00125-018-4763-3 DOI: https://doi.org/10.1007/s00125-018-4763-3
Mayer-Davis, E. J., Lawrence, J. M., Dabelea, D., Divers, J., Isom, S., Dolan, L., Imperatore, G., Linder, B., Marcovina, S., Pettitt, D. J., Pihoker, C., Saydah, S., Wagenknecht, L., & SEARCH for Diabetes in Youth Study (2017). Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012. The New England journal of medicine, 376(15), 1419–1429. https://doi.org/10.1056/NEJMoa1610187 [19] Wolfsdorf, J. I., Glaser, N., Agus, M., Fritsch, M., Hanas, R., Rewers, A., Sperling, M. A., & Codner, E. (2018). ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatric diabetes, 19 Suppl 27, 155–177. https://doi.org/10.1111/pedi.12701 DOI: https://doi.org/10.1111/pedi.12701
Rogers MAM, Kim C, Banerjee T, Lee JM. Sex differences in the incidence of type 1 diabetes: a systematic review and meta-analysis. J Womens Health. 2019;28(3):373–81.
Imkampe AK, Gulliford MC. Trends in type 1 diabetes incidence in the UK in 0- to 14-year-olds and in 15- to 34-year-olds, 1991–2008. Diabet Med. 2011;28(7):811–4. DOI: https://doi.org/10.1111/j.1464-5491.2011.03288.x
Yeung WC, Rawlinson WD, Craig ME. Enterovirus infection and type 1 diabetes mellitus: systematic review and meta-analysis of observational molecular studies. BMJ. 2011;342:d35. DOI: https://doi.org/10.1136/bmj.d35
Pulungan AB, Annisa D, Sirma I. Insiden dan tren prevalensi diabetes melitus tipe 1 pada anak di Indonesia: sebuah tinjauan. Sari Pediatri. 2019;20(6):392–400. DOI: https://doi.org/10.14238/sp20.6.2019.392-400
Ikatan Dokter Anak Indonesia (IDAI). Registri DM Tipe-1 pada anak: laporan tahun 2018. Jakarta: IDAI; 2019.
Pulungan AB, Fadiana G, Annisa D. Type 1 diabetes mellitus in children: experience in Indonesia. Clin Pediatr Endocrinol. 2021;30(1):11–18. DOI: https://doi.org/10.1297/cpe.30.11
Cleary A, Backlund JYC, Ge-nuth SM, Lachin JM, Orchard TJ, Raskin P, et al. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes [Internet]. Vol. 25, Patricia N Engl J Med. 2005. Available from: www.nejm.org
Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment. Diabetes Technology & Therapeutics. 2011;13(8):713-720
Institution of Basal-Bolus Therapy at Diagnosis for Children With Type 1 Diabetes Mellitus. Pediatric Diabetes. 2008;9(1):39-45
Freeland, Barbara DNP, RN, ACNS-BC, CDE; Farber, Margo S. PharmD. A Review of Insulin for the Treatment of Diabetes Mellitus. Home Healthcare Now 34(8):p 416-423, September 2016. | DOI: 10.1097/NHH.0000000000000446 DOI: https://doi.org/10.1097/NHH.0000000000000446
Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes: Meta-analysis of randomized controlled trials. Diabetes Care. 2011;34(2):510-517
Rubin R. Aspart Insulin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK500022/
U.S. Food and Drug Administration. Levemir (insulin detemir) injection prescribing information. Silver Spring (MD): FDA; 2023. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021536s055lbl.pdf
Yuliasari, I.A., Anggriani, Y., & Utami R, H. (2022). Outcome Klinik Berdasarkan Pemilihan Jenis Insulin pada Pasien Diabetes Mellitus Tipe 2. Farmasains : Jurnal Ilmiah Ilmu Kefarmasian DOI: https://doi.org/10.22236/farmasains.v9i2.6931
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., Ceriello, A., & Esposito, K. (2011). Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes care, 34(2), 510–517. https://doi.org/10.2337/dc10-1710 DOI: https://doi.org/10.2337/dc10-1710
Nurlaelah N, Yuniarti E, Maifitrianti M. Potential drug interactions with antidiabetic agents in hospitalized patients at a public hospital in Bandung, Indonesia. Asian J Pharm Clin Res. 2015;8(4):310-3.
Holstein A, Beil W. Oral antidiabetic drug interactions with common drugs: clinical importance and management. Diabetes Obes Metab. 2009;11(5):423-32. doi:10.1111/j.1463-1326.2009.01020.x
John M, Clements JN. Insulin and drug interactions. Clin Diabetes. 2019;37(3):276-81. doi:10.2337/cd18-0087
American Diabetes Association. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl.1):S1-S166. doi:10.2337/dc24-Sint DOI: https://doi.org/10.2337/dc24-SINT
Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract. 2009;15(5):469–74. DOI: https://doi.org/10.4158/EP08331.RAR
Holstein A, Beil W. Oral antidiabetic drug interactions with common drugs: clinical importance and management. Diabetes Obes Metab. 2009;11(5):423-32. doi:10.1111/j.1463-1326.2009.01020.x DOI: https://doi.org/10.1517/17425250902806424
Heinemann L. Pharmacokinetic and pharmacodynamic variability of insulin analogues. Diabetes Obes Metab. 2002;4(5):360-9. doi:10.1046/j.1463-1326.2002.00204.x DOI: https://doi.org/10.1046/j.1463-1326.2002.00204.x
Nurlaelah N, Yuniarti E, Maifitrianti M. Potential drug interactions with antidiabetic agents in hospitalized patients at a public hospital in Bandung, Indonesia. Asian J Pharm Clin Res. 2015;8(4):310-3
Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C, et al. Appropriate prescribing in elderly people: how well can it be measured and optimized? Lancet. 2007;370(9582):173-84. doi:10.1016/S0140-6736(07)61091-5 DOI: https://doi.org/10.1016/S0140-6736(07)61091-5
Palmer BF, Clegg DJ. Electrolyte and acid–base disturbances induced by insulin therapy. Endocrinol Metab Clin North Am. 2018;47(1):135–50.
Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335–43. [46] Barker, H. L., Morrison, D., Llano, A., Sainsbury, C. A. R., & Jones, G. C. (2023). Practical Guide to Glucocorticoid Induced Hyperglycaemia and Diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders, 14(5), 937–945. https://doi.org/10.1007/s13300-023-01393-6 [47] Takizawa, H., & Shimamoto, K. (1999). Nihon rinsho. Japanese journal of clinical medicine, 57(5), 1137–1140 DOI: https://doi.org/10.1007/s13300-023-01393-6
Holstein A, Stege H, Egberts E. Pharmacokinetic drug interactions in patients with diabetes. Clin Pharmacokinet. 2003;42(6):507-26. doi:10.2165/00003088-200342060-00002 DOI: https://doi.org/10.2165/00003088-200342060-00002
Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-9. doi:10.1056/NEJM199602293340906 DOI: https://doi.org/10.1056/NEJM199602293340906
Reaven GM. Insulin resistance, hypertension, and cardiovascular disease. J Clin Endocrinol Metab. 1991;73(6):1315-20. doi:10.1210/jcem-73-6-1315
Tatti P, Home P. Combined insulin and oral hypoglycaemic therapy in type 2 diabetes. Diabetes Metab Res Rev. 2002;18(Suppl 3):S23-8. doi:10.1002/dmrr.262 DOI: https://doi.org/10.1002/dmrr.278
Khedr A, El-Sherif A. Role of clinical pharmacists in preventing drug–drug interactions in patients with diabetes mellitus. Int J Clin Pharm. 2019;41:725-33. doi:10.1007/s11096-019-00893-6
Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65. DOI: https://doi.org/10.1517/14740338.2013.827660
Salwe KJ, Kalyansundaram D, Bahurupi YA, Pathak A. A study on polypharmacy and potential drug–drug interactions among elderly patients admitted in Department of Medicine of a tertiary care hospital in Puducherry. J Clin Diagn Res. 2016;10(2):FC06–FC10. DOI: https://doi.org/10.7860/JCDR/2016/16284.7273
Juurlink DN. Drug interactions with oral hypoglycemic agents: a guide for clinicians. CMAJ. 2016;188(17–18):1299–306.
Beijnen JH, Schellens JHM. Drug interactions in oncology. Lancet Oncol. 2004;5(8):489–96. DOI: https://doi.org/10.1016/S1470-2045(04)01528-1
Strasser, B., & Pesta, D. (2013). Resistance training for diabetes prevention and therapy: experimental findings and molecular mechanisms. BioMed research international, 2013, 805217. https://doi.org/10.1155/2013/805217 DOI: https://doi.org/10.1155/2013/805217
Gloyn, A. L., Pearson, E. R., Antcliff, J. F., Proks, P., Bruining, G. J., Slingerland, A. S., Howard, N., Srinivasan, S., Silva, J. M., Molnes, J., Edghill, E. L., Frayling, T. M., Temple, I. K., Mackay, D., Shield, J. P., Sumnik, Z., van Rhijn, A., Wales, J. K., Clark, P., Gorman, S., … Hattersley, A. T. (2004). Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. The New England journal of medicine, 350(18), 1838–1849. https://doi.org/10.1056/NEJMoa032922 DOI: https://doi.org/10.1056/NEJMoa032922